Anti-Phospho-FGFR4 Antibody (FITC)
Rabbit polyclonal antibody to Phospho-FGFR4 (FITC) from FabGennix (PFGFR4-FITC).
|Name:||Anti-Phospho-FGFR4 Antibody (FITC)|
|Description:||Rabbit polyclonal antibody to Phospho-FGFR4 (FITC)|
|Applications:||ELISA, IP, WB|
|Dilutions:||ELISA: 1:10,000; ELISA: 1:10,000; Immunoprecipitation: 1:150; Western Blot: 1:500|
|Reactivity:||Human, Mouse, Rat|
|Immunogen:||Synthetic peptide taken within amino acid region 530-580 on human Fibroblast growth factor receptor 4 variant.|
|Concentration:||0.55-0.75 µg/µl in antibody stabilization buffer|
|Storage:||-20⁰C for long term storage|
|Function:||Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.|
|Tissue Specificity:||Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines.|
|Involvement in Disease:||Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.|
|Sequence Similarities:||Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.|
|Post-Translational Modification:||N-glycosylated. Full maturation of the glycan chains in the Golgi is essential for high affinity interaction with FGF19.|
|Cellular Location:||Cell membrane. Endosome. Endoplasmic reticulum.
Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane.
Please Note: Anti-Phospho-FGFR4 Antibody (FITC) is for research use only. It is not intended for diagnostic of therapeutic use.